|
FDA Stays Complete Response on Chelsea’s Northera NDA, Pans Amended Data Plan
The FDA has notified Chelsea Therapeutics that its proposal for using initial results from an ongoing clinical trial of its Northera neurogenic orthostatic hypotension (NOH) drug is not enough to undo the complete response letter it received in March, the orphan-drug maker says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives